Fast track — ArticlesEffect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study
Introduction
HIV infection is associated with an increased risk of several cancers.1, 2, 3 Since the introduction of combination antiretroviral therapy (cART) in 1996, the incidence of AIDS-defining cancers has decreased, whereas the relative frequency of non-AIDS-defining cancers has risen.4, 5, 6 Patients with HIV have a higher risk of both AIDS-defining and non-AIDS-defining cancers than does the general population.4, 5, 7, 8 HIV-infected patients and immunosuppressed organ-transplant recipients have an increased risk of developing malignancies associated with Epstein–Barr virus, human herpesvirus 8, hepatitis B and C viruses (HBV and HCV), and human papillomavirus (HPV), and both populations have a heightened risk of lung cancer.9 Although immune deficiency is an obvious feature shared by these two populations, the effect of HIV infection itself and antiretroviral therapy on the risk of specific cancers is controversial.2, 3 We examined the incidence rates of seven specific cancers in HIV-infected patients according to the extent of immunodeficiency, viral load, and antiretroviral treatment.
Section snippets
Patients
The French Hospital Database on HIV (FHDH-ANRS CO4) is a large prospective hospital cohort in which enrolment is continuing.10 Sociodemographic, clinical, therapeutic, and laboratory data are collected at least every 6 months. All participating HIV-infected patients provided written informed consent, and the database received approval by the Commission Nationale Informatique et Liberté (CNIL). The cohort was launched in 1992 in 62 French university hospitals; however, since cART became widely
Results
We investigated the incidence of seven malignancies in 52 278 patients, with 253 353 person-years of follow-up (median 4·9 years, IQR 2·1–7·9; figure and table 1). 43 500 (83%) patients were not taking cART at study entry. In the overall population, the baseline median CD4 count was 325 cells per μL (IQR 177–491) and median viral load was 4·18 log10 copies per mL (3·13–4·94 log10). 187 468 (73%) patients received cART for the total follow-up period.
Kaposi's sarcoma was diagnosed in 565 patients
Discussion
We investigated the effect of immunodeficiency, viral replication, and cART on the incidence rates of both AIDS-defining and non-AIDS-defining cancers. Current CD4 cell count was the only factor predictive of Hodgkin's lymphoma, lung cancer, and liver cancer, whereas current CD4 cell count, current viral load, and absence of cART therapy were risk factors for Kaposi's sarcoma and non-Hodgkin lymphoma. Current CD4 cell count and absence of cART were both associated with cervical cancer. Finally,
References (34)
- et al.
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis
Lancet
(2007) - et al.
Management of AIDS-related Kaposi's sarcoma
Lancet Oncol
(2007) - et al.
Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS
Blood
(2006) Hodgkin lymphoma: to the HAART of the matter
Blood
(2006)- et al.
AIDS-related malignancies: state of the art and therapeutic challenges
J Clin Oncol
(2008) - et al.
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity
BMJ
(2009) - et al.
AIDS-defining and non-AIDS-defining malignancies: cancer occurence in the antiretroviral era
Curr Opin Oncol
(2007) - et al.
Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003
Ann Intern Med
(2008) - et al.
Cancer risk in people infected with human immunodeficiency virus in the United States
Int J Cancer
(2008) - et al.
Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study
AIDS
(2009)
Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients
J Clin Oncol
Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy
J Natl Cancer Inst
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
Ann Intern Med
AIDS and non-AIDS defining malignancies in HIV-infected patients: the 2006 ONCOVIH French study
Antivir Ther
Model selection and inference. A practical information-theoretic approach
Changes in cancer mortality among HIV-infected patients: the mortality 2005 survey
Clin Infect Dis
HIV infection and the risk of cancers with and without a known infectious cause
AIDS
Cited by (458)
Malignant lymphoma after liver transplantation for liver cirrhosis caused by human immunodeficiency virus and hepatitis C virus co-infection
2023, Journal of Infection and ChemotherapyComorbidity and life expectancy in shared decision making for lung cancer screening
2022, Seminars in OncologyCitation Excerpt :However, there is evidence for an increased risk of lung cancer independent of smoking associated with several HIV-related risk factors [89,90]. While lung cancer can develop at any Cluster of differentiation 4 (CD4) lymphocyte count, immunodeficiency, immune dysregulation, and chronic inflammation play a role, with higher rates of lung cancer observed in some studies with a lower CD4 cell count, a lower CD4/CD8 ratio over time, and higher levels of interleukin-6 preceding a cancer diagnosis [91-94]. Further, PWH have greater risk for chronic lung disease and pulmonary infections, which also increase risk for lung cancer; while lung complications are accentuated in PWH who have poorly controlled HIV, risks remain elevated even among those with well controlled HIV compared to uninfected persons [95,96].
Molecular Patho-mechanisms of cervical cancer (MMP1)
2022, Annals of Medicine and SurgeryThe Association of HIV Control and Immunosuppression With Risk of Non-AIDS-Defining Cancer Risk Among Patients on Antiretroviral Therapy
2024, Journal of Acquired Immune Deficiency Syndromes
- ‡
Members listed in webappendix